Two thirds of patients with idiopathic dilated cardiomyopathy and “Sudden Cardiac Death in Heart Failure Trial (SCD–HeFT) criteria,” at presentation did not maintain implantable cardioverter–defibrillator indications 3 to 9 months later with optimal medical therapy. Their long–term outcome was excellent, similar to that observed for patients who had never met the “SCD–HeFT criteria.”